"Weight-Loss Drug Stocks Surge on Promising Trial Results and High Demand"

Shares of Eli Lilly and Novo Nordisk surged to record highs after both companies reported positive developments in their weight-loss drug offerings. Eli Lilly's sales of its diabetes and weight loss drug Mounjaro exceeded expectations, driving the company's revenue up 28% in the fiscal quarter. Novo Nordisk's stock rose following promising clinical trial results for its obesity drug Wegovy, which reduced the risk of major adverse cardiovascular events by 20%. The popularity of weight-loss drugs is on the rise, with sales of Mounjaro and Novo Nordisk's Ozempic reaching significant levels.